HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU cites cosmetic trade issues

This article was originally published in The Rose Sheet

Executive Summary

Lack of progress on cosmetics regulatory cooperation between the EU and U.S. is viewed as potential trade barrier in the European Union's Report on U.S. Barriers to Trade and Investment released by the European Commission Dec. 19. Colour Index nomenclature for color additive labeling is cited as particular concern, as no progress has been made on industry requests to allow European-derived CI numbers in place of FDA-required nomenclature in the U.S. "The EU harmonized the majority of its labeling system with the U.S. nomenclature system, the major difference being the colour identifications used," the EU points out, adding, "FDA should act on the petition and develop a proposal for public comment." Admission of European sunscreen products into the U.S. market also is cited as a concern, as well as labeling requirements for OTC sunscreens...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS011822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel